Mogelijk gemaakt door Google TranslateTranslate
Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Latest Press Releases
View all
TimeHeadline
29m agoNayax to Report 2026 Q1 Earnings on May 12, 2026
56m agoCC Capital and OneIM Complete Acquisition of Insignia Financial Limited, Australia's Leading Diversified Wealth Management Group
1h agoCanadian Gold Resources Strengthens Board with Capital Markets Veteran Kenneth Chernin
1h agoWaraba Gold Signs Binding Agreement to Establish Joint Venture Relating to Tengrela South Exploration Permit Application in Cote d'Ivoire
1h agoSierra Madre Announces Shareholder Approval of Acquisition of Del Toro Silver Mine
Cogent Biosciences Inc logo

Cogent Biosciences Inc

About

Cogent Biosciences Inc (NASDAQ:COGT) — investor relations, events, news, and company updates on 6ix.

Latest News

Apr 21 2026
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 17 2026
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Apr 1 2026
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
Mar 16 2026
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Feb 28 2026
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Financials

Revenue
$0
Market Cap
$5.75 B
EPS
-2.16

Community Chat

Ask AI

6ix6ixAIEvents